A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

• Published in: The journal of clinical psychiatry Vol. 65 Suppl 18; p. 47
• Main Authors: McQuade, Robert D, Stock, Elyse, Marcus, Ron, Jody, Darlene, Gharbia, Neveen A, Vanveggel, Simon, Archibald, Don, Carson, William H
• Format: Journal Article
• Language: English
• Published: United States 2004
• Subjects: Acute Disease; Adult; Antipsychotic Agents - adverse effects; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Aripiprazole; Benzodiazepines - adverse effects; Benzodiazepines - pharmacology; Benzodiazepines - therapeutic use; Double-Blind Method; Female; Humans; Hyperlipidemias - chemically induced; Incidence; Lipids - blood; Male; Obesity - chemically induced; Obesity - epidemiology; Piperazines - adverse effects; Piperazines - pharmacology; Piperazines - therapeutic use; Psychiatric Status Rating Scales; Quinolones - adverse effects; Quinolones - pharmacology; Quinolones - therapeutic use; Schizophrenia - diagnosis; Schizophrenia - drug therapy; Schizophrenia - prevention & control; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain - drug effects

Weight gain is a side effect of therapy with many atypical antipsychotics and may have important clinical repercussions with respect to long-term health and treatment compliance. The primary objective of this double-blind study was to compare the safety and tolerability of aripiprazole and olanzapin...